- Home
- BA vs AMGN Comparison
BA vs AMGN Comparison
Compare BA & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BA
- AMGN
- Stock Information
- Founded
- BA 1916
- AMGN 1980
- Country
- BA United States
- AMGN United States
- Employees
- BA N/A
- AMGN N/A
- Industry
- BA Aerospace
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BA Industrials
- AMGN Health Care
- Exchange
- BA Nasdaq
- AMGN Nasdaq
- Market Cap
- BA 167.8B
- AMGN 156.3B
- IPO Year
- BA N/A
- AMGN N/A
- Fundamental
- Price
- BA $229.96
- AMGN $293.72
- Analyst Decision
- BA Strong Buy
- AMGN Hold
- Analyst Count
- BA 18
- AMGN 18
- Target Price
- BA $232.00
- AMGN $319.33
- AVG Volume (30 Days)
- BA 7.3M
- AMGN 2.1M
- Earning Date
- BA 07-29-2025
- AMGN 08-05-2025
- Dividend Yield
- BA N/A
- AMGN 3.24%
- EPS Growth
- BA N/A
- AMGN 110.88
- EPS
- BA N/A
- AMGN 12.23
- Revenue
- BA $75,327,000,000.00
- AMGN $34,917,000,000.00
- Revenue This Year
- BA $32.22
- AMGN $7.96
- Revenue Next Year
- BA $15.20
- AMGN $1.70
- P/E Ratio
- BA N/A
- AMGN $24.02
- Revenue Growth
- BA 2.41
- AMGN 12.88
- 52 Week Low
- BA $128.88
- AMGN $253.30
- 52 Week High
- BA $242.69
- AMGN $339.17
- Technical
- Relative Strength Index (RSI)
- BA 54.60
- AMGN 49.79
- Support Level
- BA $223.60
- AMGN $292.11
- Resistance Level
- BA $236.45
- AMGN $301.47
- Average True Range (ATR)
- BA 5.08
- AMGN 6.21
- MACD
- BA -0.80
- AMGN 0.29
- Stochastic Oscillator
- BA 57.80
- AMGN 59.02
About BA Boeing Company (The)
Boeing is a major aerospace and defense firm. It operates in three segments: commercial airplanes; defense, space, and security; and global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with defense contractors such as Lockheed Martin and Northrop Grumman to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.